文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在两次幽门螺杆菌治疗失败后使用左氧氟沙星进行三线挽救治疗。

Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.

作者信息

Gisbert Javier P, Castro-Fernández Manuel, Bermejo Fernando, Pérez-Aisa Angeles, Ducons Julio, Fernández-Bermejo Miguel, Bory Felipe, Cosme Angel, Benito Luis-Miguel, López-Rivas Laureano, Lamas Eloisa, Pabón Manuel, Olivares David

机构信息

Hospital de la Princesa, Madrid, Spain.

出版信息

Am J Gastroenterol. 2006 Feb;101(2):243-7. doi: 10.1111/j.1572-0241.2006.00457.x.


DOI:10.1111/j.1572-0241.2006.00457.x
PMID:16454825
Abstract

AIM: Eradication therapy with proton pump inhibitor, clarithromycin and amoxicillin fails in a considerable number of cases. A rescue therapy still fails in more than 20% of the cases. Our aim was to evaluate the efficacy and tolerability of a third-line levofloxacin-based regimen in patients with two consecutive Helicobacter pylori eradication failures. DESIGN: Prospective multicenter study. PATIENTS: In whom a first treatment with omeprazole-clarithromycin-amoxicillin and a second with omeprazole-bismuth-tetracycline-metronidazole (or ranitidine bismuth citrate with these antibiotics) had failed. INTERVENTION: A third eradication regimen with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole (20 mg b.i.d.) was prescribed for 10 days. OUTCOME: Eradication was confirmed with 13C-urea breath test 4-8 wk after therapy. RESULTS: One-hundred patients were initially included, and nine were lost for follow-up. All patients but five took all the medications correctly. Per-protocol and intention-to-treat eradication rates were 66% (95% CI = 56-75%) and 60% (50-70%). Adverse effects were reported in 25% of the patients, mainly including metallic taste (8%), nausea (8%), myalgia/arthralgia (5%), and diarrhea (4%); none of them were severe. CONCLUSION: Levofloxacin-based rescue therapy constitutes an encouraging empirical third-line strategy after multiple previous H. pylori eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, and tetracycline.

摘要

目的:使用质子泵抑制剂、克拉霉素和阿莫西林进行根除治疗,在相当多的病例中会失败。补救治疗仍有超过20%的病例失败。我们的目的是评估在连续两次根除幽门螺杆菌失败的患者中,基于左氧氟沙星的三线治疗方案的疗效和耐受性。 设计:前瞻性多中心研究。 患者:初次使用奥美拉唑-克拉霉素-阿莫西林治疗及第二次使用奥美拉唑-铋剂-四环素-甲硝唑(或雷尼替丁枸橼酸铋与这些抗生素联用)治疗均失败的患者。 干预:给予为期10天的含左氧氟沙星(500毫克,每日两次)、阿莫西林(1克,每日两次)和奥美拉唑(20毫克,每日两次)的第三次根除方案。 结果:治疗:治疗后4至8周,通过13C-尿素呼气试验确认根除情况。 结果:最初纳入100例患者,9例失访。除5例患者外,所有患者均正确服用了所有药物。符合方案集和意向性分析的根除率分别为66%(95%可信区间=56-75%)和60%(50-70%)。25%的患者报告有不良反应,主要包括金属味(8%)、恶心(8%)、肌痛/关节痛(5%)和腹泻(4%);均不严重。 结论:在先前多次使用阿莫西林、克拉霉素、甲硝唑和四环素等关键抗生素根除幽门螺杆菌失败后,基于左氧氟沙星的补救治疗是一种令人鼓舞的经验性三线策略。

相似文献

[1]
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.

Am J Gastroenterol. 2006-2

[2]
Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.

Am J Gastroenterol. 2008-1

[3]
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.

Am J Gastroenterol. 2006-8

[4]
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.

J Clin Gastroenterol. 2013-2

[5]
Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.

Scand J Gastroenterol. 2013-6

[6]
Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.

Aliment Pharmacol Ther. 2008-2-15

[7]
Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures.

Aliment Pharmacol Ther. 2006-11-15

[8]
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.

J Gastroenterol Hepatol. 2005-4

[9]
Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Dig Dis Sci. 2013-10-15

[10]
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

Aliment Pharmacol Ther. 2012-2-28

引用本文的文献

[1]
First-Line Levofloxacin-Based Triple Therapy Versus Standard Bismuth-Based Quadruple Therapy for Eradication in Saudi Arabia: A Retrospective Single-Center Study.

Health Sci Rep. 2025-2-5

[2]
Rifabutin for the Treatment of Infection: A Review.

Pathogens. 2020-12-28

[3]
Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones.

Molecules. 2020-11-2

[4]
Current Status of the Third-Line Eradication.

Gastroenterol Res Pract. 2018-5-2

[5]
Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of in Peptic Ulcer Disease.

Gut Liver. 2017-3-15

[6]
Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection.

Therap Adv Gastroenterol. 2016-7

[7]
Vaccine against Helicobacter pylori: Inevitable approach.

World J Gastroenterol. 2016-3-21

[8]
Fluoroquinolone-based protocols for eradication of Helicobacter pylori.

World J Gastroenterol. 2014-7-21

[9]
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.

J Gastroenterol. 2013-1-11

[10]
[Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Aten Primaria. 2012-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索